Inhibrx, Inc. Contracts & Agreements

Termination Agreement, dated February (Filed With SEC on February 28, 2024)

Amendment to Warrants to Purchase Stock, dated January 22, 2024, by and between Inhibrx, Inc. and Oxford Finance LLC (Filed With SEC on January 23, 2024)

Form of Agreement to Pre-Funded Warrant to Purchase Common Stock and Securities Purchase Agreement, dated January 22, 2024, by and between Inhibrx, Inc. and each holder of the... (Filed With SEC on January 23, 2024)

Separation and Distribution Agreement, dated as of January 22, 2024, by and among Inhibrx, Inc., Ibex SpinCo, Inc., and Aventis Inc (Filed With SEC on January 23, 2024)

Agreement and Plan of Merger, dated as of January 22, 2024, by and among Inhibrx, Inc., Aventis Inc., and Art Acquisition Sub, Inc (Filed With SEC on January 23, 2024)

Inhibrx, Inc. Clawback Policy (Filed With SEC on November 9, 2023)

Form of Securities Purchase Agreement (Filed With SEC on August 29, 2023)

Form of Pre-Funded Warrant to Purchase Common Stock (Filed With SEC on August 29, 2023)

Second Amended and Restated Executive Employment Agreement, effective as of January 1, 2023, by and between the Company and Kelly Deck (Filed With SEC on November 7, 2022)

Third Amended and Restated Executive Employment Agreement, effective as of January 1, 2023, by and between the Company and Mark Lappe (Filed With SEC on November 7, 2022)

Fifth Amendment to Loan and Security Agreement, dated June 15, 2022, by and between the Company and Oxford Finance LLC (Filed With SEC on June 16, 2022)

Separation Letter Agreement, effective as of February 1, 2022, by and between the Registrant and Klaus Wagner, M.D., Ph.D (Filed With SEC on February 28, 2022)

Fourth Amendment to Loan and Security Agreement, dated February 18, 2022, by and between the Company and Oxford Finance LLC (Filed With SEC on February 22, 2022)

Amended and Restated Executive Employment Agreement, effective as of January 1, 2022, by and between the Company and Kelly Deck (Filed With SEC on November 9, 2021)

Second Amended and Restated Executive Employment Agreement, effective as of January 1, 2022, by and between the Company and Brendan Eckelman, Ph.D (Filed With SEC on November 9, 2021)

Second Amended and Restated Executive Employment Agreement, effective as of January 1, 2022, by and between the Company and Klaus Wagner, M.D., Ph.D (Filed With SEC on November 9, 2021)

Second Amended and Restated Executive Employment Agreement, effective as of January 1, 2022, by and between the Company and Mark Lappe (Filed With SEC on November 9, 2021)

Third Amendment to Loan and Security Agreement, dated June 18, 2021, by and between the Company and Oxford Finance LLC (Filed With SEC on June 21, 2021)

Description of the Registrants Securities (Filed With SEC on March 12, 2021)

First Amendment to Loan and Security Agreement, dated November 12, 2020, by and between the Registrant and Oxford Finance LLC (Filed With SEC on November 13, 2020)

Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (to be effective upon completion of this offering) (Filed With SEC on August 12, 2020)

Executive Employment Agreement, effective as of August 7, 2020, by and between the Registrant and Kelly Deck (Filed With SEC on August 12, 2020)

Amended and Restated Executive Employment Agreement, effective as of August 7, 2020, by and between the Registrant and Brendan Eckelman, Ph.D (Filed With SEC on August 12, 2020)

Amended and Restated Executive Employment Agreement, effective as of August 7, 2020, by and between the Registrant and Klaus Wagner, M.D., Ph.D (Filed With SEC on August 12, 2020)

Amended and Restated Executive Employment Agreement, effective as of August 7, 2020, by and between the Registrant and Mark Lappe (Filed With SEC on August 12, 2020)

Form of Underwriting Agreement (Filed With SEC on August 12, 2020)

Form of Warrant to Purchase Stock by and between the Registrant and Oxford Finance LLC (Filed With SEC on July 28, 2020)

Second Amendment to Right of First Refusal and Co-Sale Agreement, dated April 6, 2020, by and among the Registrant and the investors named therein (Filed With SEC on July 28, 2020)

Form of Indemnification Agreement (Filed With SEC on July 28, 2020)

Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (to be effective upon completion of this offering) (Filed With SEC on July 28, 2020)

Amendment to Convertible Promissory Note, dated April 6, 2020, by and between the Registrant and DRAGSA 50 LLC (Filed With SEC on July 28, 2020)

Form of Convertible Promissory Note, dated April 6, 2020, by and between the Registrant and each of DRAGSA 50 LLC and certain other investors (Filed With SEC on July 28, 2020)

Option and License Agreement, dated June 9, 2020, by and between the Registrant and bluebird bio, Inc (Filed With SEC on July 28, 2020)

Loan and Security Agreement, dated July 15, 2020, by and between the Registrant and Oxford Finance LLC (Filed With SEC on July 28, 2020)

Amendment No. 1 to Amended and Restated Master Services Agreement, dated December 11, 2019, by and between the Registrant and WuXi Biologics (Hong Kong) Limited (Filed With SEC on July 28, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on July 28, 2020)

Second Amended and Restated Investors Rights Agreement, dated April 6, 2020, by and among the Registrant and the investors named therein (Filed With SEC on July 28, 2020)

Amendment to Inhibrx, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan (currently in effect) (Filed With SEC on August 20, 2019)

First Amendment to Option Agreement, dated August 19, 2019, by and between the Registrant and Chiesi Farmaceutici S.p.A (Filed With SEC on August 20, 2019)

Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (to be effective upon completion of this offering) (Filed With SEC on August 20, 2019)

Amendment to License Agreement, dated November 23, 2018, by and among the Registrant, INBRX 103, LLC and Celgene Corporation (Filed With SEC on June 3, 2019)

Amended and Restated Investors Rights Agreement, dated May 20, 2019, by and between the Registrant and the investors named therein (Filed With SEC on June 3, 2019)

License Agreement, dated July 1, 2013, by and between INBRX 103, LLC and Celgene Corporation (Filed With SEC on June 3, 2019)

Form of Restricted Stock Agreement under the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (to be effective upon completion of this offering) (Filed With SEC on June 3, 2019)

Form of Stock Option Grant Notice under the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (to be effective upon completion of this offering) (Filed With SEC on June 3, 2019)

Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan (to be effective upon completion of this offering) (Filed With SEC on June 3, 2019)

Form of Restricted Stock Agreement under the 2017 Employee, Director and Consultant Equity Incentive Plan (currently in effect) (Filed With SEC on June 3, 2019)

Form of Stock Option Grant Notice under the 2017 Employee, Director and Consultant Equity Incentive Plan (currently in effect) (Filed With SEC on June 3, 2019)

2017 Employee, Director and Consultant Equity Incentive Plan (currently in effect) (Filed With SEC on June 3, 2019)

Executive Employment Agreement, effective as of January 1, 2019, by and between the Registrant and Brendan Eckelman, Ph.D (Filed With SEC on June 3, 2019)

Executive Employment Agreement, effective as of January 1, 2019, by and between the Registrant and Klaus Wagner, M.D., Ph.D (Filed With SEC on June 3, 2019)

Executive Employment Agreement, effective as of January 1, 2019, by and between the Registrant and Mark Lappe (Filed With SEC on June 3, 2019)

Form of Indemnification Agreement (Filed With SEC on June 3, 2019)

First Amendment to Right of First Refusal and Co-Sale Agreement, dated May 20, 2019, by and between the Registrant and the investors named therein (Filed With SEC on June 3, 2019)

Right of First Refusal and Co-Sale Agreement, dated April 30, 2018, by and between the Registrant and the investors named therein (Filed With SEC on June 3, 2019)

Form of Common Stock Certificate (Filed With SEC on June 3, 2019)

License Agreement, dated June 21, 2017, by and between the Registrant and Hangzhou Just Biotherapeutics Co., Ltd (Filed With SEC on June 3, 2019)

Technical Services Agreement, dated March 19, 2018, by and between the Registrant and Hangzhou Just Biotherapeutics Co., Ltd (Filed With SEC on June 3, 2019)

Technical Services Agreement, dated October 6, 2018, by and between the Registrant and Hangzhou Just Biotherapeutics Co., Ltd (Filed With SEC on June 3, 2019)

License Agreement, dated February 28, 2018, by and between the Registrant and Elpiscience Biopharmaceuticals, Inc (Filed With SEC on June 3, 2019)

License Agreement, dated April 30, 2018, by and between the Registrant and Elpiscience Biopharmaceuticals, Inc (Filed With SEC on June 3, 2019)

License Agreement, dated December 20, 2018, by and between the Registrant and bluebird bio, Inc (Filed With SEC on June 3, 2019)

Loan and Security Agreement, dated March 31, 2015, by and between the Registrant and Oxford Finance LLC (Filed With SEC on June 3, 2019)

First Amendment, Waiver and Consent to Loan and Security Agreement, dated August 15, 2016, by and between the Registrant and Oxford Finance LLC (Filed With SEC on June 3, 2019)

Second Amendment to Loan and Security Agreement, dated December 22, 2016, by and between the Registrant and Oxford Finance LLC (Filed With SEC on June 3, 2019)

Consent and Third Amendment to Loan and Security Agreement, dated April 30, 2018, by and among the Registrant, Oxford Finance LLC and the Lenders listed therein (Filed With SEC on June 3, 2019)

Amended and Restated Master Services Agreement, dated August 28, 2018, by and between the Registrant and WuXi Biologics (Hong Kong) Limited (Filed With SEC on June 3, 2019)

First Amendment to Lease, dated May 21, 2019, by and between the Registrant and HCP TPSP, LLC (Filed With SEC on June 3, 2019)

Convertible Promissory Note, dated May 20, 2019, by and between the Registrant and DRAGSA 50 LLC (Filed With SEC on June 3, 2019)

Option Agreement, dated May 29, 2019, by and between the Registrant and Chiesi Farmaceutici S.p.A (Filed With SEC on June 3, 2019)

Lease Agreement, dated September 8, 2017, by and between the Registrant and HCP TPSP, LLC (Filed With SEC on June 3, 2019)

Category

Industry

Companies

Contracts

Inhibrx, Inc. Contracts & Agreements